Try
Aurinia Pharmaceuticals Inc.
AUPHUnited States
50 filed reports · 585 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
50 reports · Dec 2017 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 52 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Current · 8-KSEC EDGAR | 22 | 48 | Jun 2021 to Jun 2026 |
| Quarterly · 10-QSEC EDGAR | 17 | 2,777 | Mar 2021 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 6 | 2,768 | Dec 2020 to Dec 2025 |
| Annual · 40-FSEC EDGAR | 3 | 901 | Dec 2017 to Dec 2019 |
| Annual · 10-K/ASEC EDGAR | 2 | 2 | Dec 2020 to Dec 2023 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 6, 2026 | 2 | Open |
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 342 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 7, 2026 | 4 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 211 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 26, 2026 | 2 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 26, 2026 | 807 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 216 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Nov 4, 2025 | 2 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Jul 31, 2025 | 2 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Jul 31, 2025 | 136 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 12, 2025 | 141 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | May 12, 2025 | 2 | Open |
Financial data
585 concepts · 6,496 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial570 concepts · 6,283 facts · Dec 2015 to Aug 2026
- Revenue40 · Dec 2016 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents38 · Dec 2017 to Jun 2026
- Net income loss38 · Dec 2018 to Jun 2026
- Operating income loss38 · Dec 2018 to Jun 2026
- Stockholders equity (US GAAP)38 · Dec 2017 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value34 · Dec 2018 to Jun 2026
- Allocated share based compensation expense34 · Dec 2018 to Jun 2026
- Amortization of intangible assets34 · Dec 2018 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect34 · Dec 2018 to Jun 2026
- General and administrative expense (US GAAP)34 · Dec 2018 to Jun 2026
- Income tax expense benefit34 · Dec 2018 to Jun 2026
- Increase decrease in inventories34 · Dec 2018 to Jun 2026
- Increase decrease in prepaid expense34 · Dec 2018 to Jun 2026
- Increase decrease in receivables34 · Dec 2018 to Jun 2026
- Net cash provided by used in financing activities34 · Dec 2018 to Jun 2026
- Net cash provided by used in investing activities34 · Dec 2018 to Jun 2026
- Net cash provided by used in operating activities34 · Dec 2018 to Jun 2026
- Operating expenses (US GAAP)34 · Dec 2018 to Dec 2025
- Other noncash income expense34 · Dec 2018 to Jun 2026
- Other operating income expense net34 · Dec 2018 to Jun 2026
- Payments to acquire marketable securities34 · Dec 2018 to Jun 2026
- Payments to acquire other productive assets34 · Dec 2018 to Jun 2026
- Proceeds from sale and maturity of marketable securities34 · Dec 2018 to Jun 2026
- Proceeds from stock options exercised34 · Dec 2018 to Jun 2026
Geography11 concepts · 89 facts · Dec 2016 to Jun 2026
- Revenue37 · Dec 2016 to Dec 2025
- Finance lease interest expense17 · Dec 2022 to Jun 2026
- Finance lease right of use asset amortization17 · Dec 2022 to Jun 2026
- Applicable tax rate4 · Dec 2016 to Dec 2019
- Finance lease principal payments4 · Jun 2023 to Sep 2023
- Payments for proceeds from tenant allowance4 · Dec 2020 to Dec 2023
- Edmonton, Alberta2 · Dec 2019 to Dec 2020
- Foreign currency transaction loss before tax1 · Dec 2023
- Minimum operating lease payments1 · Dec 2018
- Monoplant1 · Jun 2023
- Victoria, British Columbia1 · Dec 2017
Product2 concepts · 76 facts · Dec 2018 to Jun 2026
- Revenue75 · Dec 2018 to Jun 2026
- Voclosporin1 · Dec 2019
Guidance2 concepts · 48 facts · Aug 2021 to Aug 2026
- Revenue Guidance46 · Aug 2021 to Aug 2026
- Revenue Growth Guidance2 · May 2026
Segments
165 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service4 members · 75 facts
- Product34 · Dec 2018 to Jun 2026
- License17 · Dec 2018 to Dec 2022
- License Collaboration And Royalty Revenue15 · Dec 2021 to Jun 2026
- License Royalty And Collaboration Revenue9 · Mar 2022 to Sep 2024
Statement geographical7 members · 70 facts
- Visp Switzerland40 · Dec 2022 to Jun 2026
- JP8 · Dec 2018 to Dec 2025
- US8 · Dec 2018 to Dec 2025
- Other Country6 · Dec 2019 to Dec 2024
- Rockville Maryland4 · Dec 2020 to Dec 2023
- CN3 · Dec 2018 to Dec 2020
- Edmonton Alberta1 · Dec 2020
Geographical areas5 members · 19 facts
- CA6 · Dec 2016 to Dec 2019
- CN4 · Dec 2016 to Dec 2019
- US4 · Dec 2016 to Dec 2019
- Edmonton Alberta3 · Dec 2017 to Dec 2019
- CH2 · Dec 2016 to Dec 2017
Products and services1 member · 1 facts
- Voclosporin1 · Dec 2019
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.